Dawnrays Pharmaceutical (Holdings) Limited

HKSE 2348.HK

Dawnrays Pharmaceutical (Holdings) Limited Gross Profit Margin for the year ending December 31, 2023: 55.73%

Dawnrays Pharmaceutical (Holdings) Limited Gross Profit Margin is 55.73% for the year ending December 31, 2023, a -7.13% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Dawnrays Pharmaceutical (Holdings) Limited Gross Profit Margin for the year ending December 31, 2022 was 60.01%, a 3.52% change year over year.
Dawnrays Pharmaceutical (Holdings) Limited Gross Profit Margin for the year ending December 31, 2021 was 57.96%, a 8.83% change year over year.
Dawnrays Pharmaceutical (Holdings) Limited Gross Profit Margin for the year ending December 31, 2020 was 53.26%, a -3.21% change year over year.
Dawnrays Pharmaceutical (Holdings) Limited Gross Profit Margin for the year ending December 31, 2019 was 55.03%, a -12.25% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

HKSE: 2348.HK

Dawnrays Pharmaceutical (Holdings) Limited

CEO	Ms. Liwei Yu
IPO Date	July 11, 2003
Location	Hong Kong
Headquarters	CNT Tower
Employees	1,175
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, and oral antibiotics. It also provides and system specific medicines comprising cardiovascular systems; anti-allergic, anti-HBV, and digestive systems; urinary systems; and anti-pyretic analgesic, respiratory, and endocrine system drugs in the form of tablets, capsules, and granules. The company was founded in 1995 and is headquartered in Wan Chai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.

Key trends

Past 5 years